Organizers

President and professor of Sun Yat-sen University Cancer Center, Director of State Key Laboratory of Oncology in South China, Member of the Academic Committee of the Chinese Academy of Medical Sciences, Chairman of the Chinese Society of Clinical Oncology (CSCO), Vice-chairman of China Anti-cancer Association (CACA) and Editor in Chief of Cancer Communications.

Professor Xu has made profound contributions in the research and treatment of GI cancer, advancing both theory and practice in the field. His pioneering work has elevated China's GI cancer early diagnosis and precision treatment to an internationally advanced level. His groundbreaking contributions have redefined the immunotherapy strategy for GI cancer, driving global progress in this specialized domain. His clinical research on Toripalimab, a domestically developed innovative PD-1 antibody, garnered FDA approval in the United States on October 28, 2023. This marks a historic milestone, as it's the first time Chinese original biological monoclonal antibodies have obtained US market approval.

He has published more than 200 peer-reviewed papers in top international journals such as JAMA, Cancer Cell, Nature Medicine, Nature Materials and Lancet Oncology. His standing as a "Highly Cited Researcher" by Clarivate Analytics underscores his influence and recognition within the scientific community. He was awarded 2 times of Prizes of the State Scientific and Technological Progress Award, and the National Innovation Competition Award.

徐瑞华，中山大学肿瘤防治中心主任

中山大学肿瘤防治中心教授、主任，华南恶性肿瘤防治全国重点实验室主任。中国医学科学院学部委员，中国临床肿瘤学会理事长，中国抗癌协会副理事长，《Cancer Communications》期刊主编。

徐教授主持的研究实现了肠癌诊治理论和实践的系统创新，使我国肠癌早诊及精准治疗均处于国际先进水平。创新了消化肿瘤免疫治疗体系，引领国际消化肿瘤免疫治疗发展。徐教授负责的国产创新药PD-1抗体（特瑞普利单抗）临床研究，2023年10月28日美国FDA批准了这一新药在美国上市，这是中国原研生物单抗首次获得美国批准上市。
徐教授在国际顶级期刊JAMA、Nature Medicine、Nature Materials、Cancer Cell、Lancet Oncology等发表SCI论文200余篇，入选科睿唯安（Clarivate Analytics）全球高被引科学家。以第一完成人获国家科技进步二等奖2项、全国创新争先奖1项。

« Go Back